P
Paulo M. Hoff
Researcher at University of Texas MD Anderson Cancer Center
Publications - 87
Citations - 13588
Paulo M. Hoff is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Colorectal cancer & Capecitabine. The author has an hindex of 39, co-authored 80 publications receiving 12231 citations. Previous affiliations of Paulo M. Hoff include Albert Einstein Hospital & University of São Paulo.
Papers
More filters
Journal ArticleDOI
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem,Andrés Cervantes,René Adam,Alberto Sobrero,J.H.J.M. van Krieken,Dan Aderka,E. Aranda Aguilar,Alberto Bardelli,Al B. Benson,György Bodoky,Fortunato Ciardiello,André D'Hoore,Eduardo Díaz-Rubio,J.-Y. Douillard,Michel Ducreux,Alfredo Falcone,Axel Grothey,Thomas Gruenberger,Karin Haustermans,Volker Heinemann,Paulo M. Hoff,C.-H. Köhne,R. Labianca,Pierre Laurent-Puig,Brigette B.Y. Ma,Tim Maughan,Kei Muro,Nicola Normanno,Pia Österlund,Pia Österlund,Wim J.G. Oyen,Demetris Papamichael,George Pentheroudakis,Per Pfeiffer,Timothy J. Price,C.J.A. Punt,Jens Ricke,Arnaud Roth,R. Salazar,Werner Scheithauer,H.-J. Schmoll,Josep Tabernero,Julien Taieb,Sabine Tejpar,Harpreet Wasan,Takayuki Yoshino,Aziz Zaanan,Dirk Arnold +47 more
TL;DR: These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.
Journal ArticleDOI
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
H.-J. Schmoll,E. Van Cutsem,Alexander Stein,Vincenzo Valentini,Bengt Glimelius,Bengt Glimelius,Karin Haustermans,Bernard Nordlinger,C.J.H. van de Velde,Judith Balmaña,Jaroslaw Regula,Iris D. Nagtegaal,Regina G. H. Beets-Tan,D Arnold,Fortunato Ciardiello,Paulo M. Hoff,David J. Kerr,C.-H. Köhne,Roberto Labianca,Timothy J. Price,Werner Scheithauer,Alberto Sobrero,Josep Tabernero,Dan Aderka,S Barroso,György Bodoky,J.-Y. Douillard,H El Ghazaly,Jorge Gallardo,August Garin,Rob Glynne-Jones,Karin Jordan,A Meshcheryakov,D Papamichail,Per Pfeiffer,Ioannis Souglakos,Serdar Turhal,Andrés Cervantes +37 more
TL;DR: This ESMO guideline is recommended to be used as the basis for treatment and management decisions, delivering a clear proposal for diagnostic and treatment measures in each stage of rectal and colon cancer and the individual clinical situations.
Journal ArticleDOI
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases
Jean Nicolas Vauthey,Timothy M. Pawlik,Dario Ribero,Tsung Teh Wu,Daria Zorzi,Paulo M. Hoff,Henry Q. Xiong,Cathy Eng,Gregory Y. Lauwers,Mari Mino-Kenudson,Mauro Risio,Andrea Muratore,Lorenzo Capussotti,Steven A. Curley,Eddie K. Abdalla +14 more
TL;DR: Steatohepatitis is associated with an increased 90-day mortality after hepatic surgery and the chemotherapy regimen should be carefully considered because the risk of hepatotoxicity is significant in patients with hepatic CRM.
Journal ArticleDOI
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
Paulo M. Hoff,Rafat Ansari,Gerald Batist,John Cox,Walter Kocha,Mario Kuperminc,Jean A. Maroun,David Walde,Charles Weaver,Evelyn Harrison,Hans U. Burger,Bruno Osterwalder,A. Wong,Ralf Wong +13 more
TL;DR: Oral capecitabine was more active than 5-FU/LV in the induction of objective tumor responses and demonstrated clinically meaningful benefits over bolus 5-fu/ LV in terms of tolerability.
Journal ArticleDOI
Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas
Maria A. Kouvaraki,Jaffer A. Ajani,Paulo M. Hoff,Robert A. Wolff,Douglas B. Evans,Richard D. Lozano,James C. Yao +6 more
TL;DR: Patients with locally advanced or metastatic PEC who are treated with FAS may have a reasonable RR, and responders may experience longer PFS and OS, and the volume of metastases in the liver is the most important predictor of outcome.